281 related articles for article (PubMed ID: 29934699)
1. Novel iridium(III) iminopyridine complexes: synthetic, catalytic, and in vitro anticancer activity studies.
Kong D; Tian M; Guo L; Liu X; Zhang S; Song Y; Meng X; Wu S; Zhang L; Liu Z
J Biol Inorg Chem; 2018 Jul; 23(5):819-832. PubMed ID: 29934699
[TBL] [Abstract][Full Text] [Related]
2. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
3. Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable in vitro anticancer activity.
Li J; Guo L; Tian Z; Tian M; Zhang S; Xu K; Qian Y; Liu Z
Dalton Trans; 2017 Nov; 46(44):15520-15534. PubMed ID: 29090698
[TBL] [Abstract][Full Text] [Related]
4. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
5. DFT Investigation of the Mechanism of Action of Organoiridium(III) Complexes As Anticancer Agents.
Ritacco I; Russo N; Sicilia E
Inorg Chem; 2015 Nov; 54(22):10801-10. PubMed ID: 26492153
[TBL] [Abstract][Full Text] [Related]
6. Half-sandwich iridium N-heterocyclic carbene anticancer complexes.
Wang C; Liu J; Tian Z; Tian M; Tian L; Zhao W; Liu Z
Dalton Trans; 2017 May; 46(21):6870-6883. PubMed ID: 28405646
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands.
Yang Y; Guo L; Ge X; Shi S; Gong Y; Xu Z; Zheng X; Liu Z
J Inorg Biochem; 2019 Feb; 191():1-7. PubMed ID: 30445339
[TBL] [Abstract][Full Text] [Related]
8. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
9. Half-sandwich Iridium(III) Benzimidazole-Appended Imidazolium-Based N-heterocyclic Carbene Complexes and Antitumor Application.
Han Y; Liu X; Tian Z; Ge X; Li J; Gao M; Li Y; Liu Y; Liu Z
Chem Asian J; 2018 Dec; 13(23):3697-3705. PubMed ID: 30276978
[TBL] [Abstract][Full Text] [Related]
10. New Organometallic Tetraphenylethylene⋅Iridium(III) Complexes with Antineoplastic Activity.
Liu X; He X; Zhang X; Wang Y; Liu J; Hao X; Zhang Y; Yuan XA; Tian L; Liu Z
Chembiochem; 2019 Nov; 20(21):2767-2776. PubMed ID: 31119850
[TBL] [Abstract][Full Text] [Related]
11. The Fluorine Effect in Zwitterionic Half-Sandwich Iridium(III) Anticancer Complexes.
Yang Y; Guo L; Ge X; Zhu T; Chen W; Zhou H; Zhao L; Liu Z
Inorg Chem; 2020 Jan; 59(1):748-758. PubMed ID: 31808678
[TBL] [Abstract][Full Text] [Related]
12. Organoiridium complexes: anticancer agents and catalysts.
Liu Z; Sadler PJ
Acc Chem Res; 2014 Apr; 47(4):1174-85. PubMed ID: 24555658
[TBL] [Abstract][Full Text] [Related]
13. The potent oxidant anticancer activity of organoiridium catalysts.
Liu Z; Romero-Canelón I; Qamar B; Hearn JM; Habtemariam A; Barry NP; Pizarro AM; Clarkson GJ; Sadler PJ
Angew Chem Int Ed Engl; 2014 Apr; 53(15):3941-6. PubMed ID: 24616129
[TBL] [Abstract][Full Text] [Related]
14. Hydrosulfide Adducts of Organo-Iridium Anticancer Complexes.
Štarha P; Habtemariam A; Romero-Canelón I; Clarkson GJ; Sadler PJ
Inorg Chem; 2016 Mar; 55(5):2324-31. PubMed ID: 26863200
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes.
Gupta G; Garci A; Murray BS; Dyson PJ; Fabre G; Trouillas P; Giannini F; Furrer J; Süss-Fink G; Therrien B
Dalton Trans; 2013 Nov; 42(43):15457-63. PubMed ID: 24022745
[TBL] [Abstract][Full Text] [Related]
16. Organometallic half-sandwich iridium anticancer complexes.
Liu Z; Habtemariam A; Pizarro AM; Fletcher SA; Kisova A; Vrana O; Salassa L; Bruijnincx PC; Clarkson GJ; Brabec V; Sadler PJ
J Med Chem; 2011 Apr; 54(8):3011-26. PubMed ID: 21443199
[TBL] [Abstract][Full Text] [Related]
17. Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands.
Ludwig G; Ranđelović I; Maksimović-Ivanić D; Mijatović S; Bulatović MZ; Miljković D; Korb M; Lang H; Steinborn D; Kaluđerović GN
ChemMedChem; 2014 Jul; 9(7):1586-93. PubMed ID: 24470190
[TBL] [Abstract][Full Text] [Related]
18. Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.
Ludwig G; Mijatović S; Ranđelović I; Bulatović M; Miljković D; Maksimović-Ivanić D; Korb M; Lang H; Steinborn D; Kaluđerović GN
Eur J Med Chem; 2013 Nov; 69():216-22. PubMed ID: 24042044
[TBL] [Abstract][Full Text] [Related]
19. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
20. Similarities and differences in d
Gilewska A; Barszcz B; Masternak J; Kazimierczuk K; Sitkowski J; Wietrzyk J; Turlej E
J Biol Inorg Chem; 2019 Jun; 24(4):591-606. PubMed ID: 31115765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]